国外医药(抗生素分册)2024,Vol.45Issue(2) :74-83.

拟无枝酸菌糖肽类和聚酮类抗生素的遗传信息及生物合成途径的研究进展

Progress on Genetic Information and Biosynthetic Pathways of Glycopeptide and Polyketide Antibiotics of Amycolatopsis

牛莎莎 张萍 牛春
国外医药(抗生素分册)2024,Vol.45Issue(2) :74-83.

拟无枝酸菌糖肽类和聚酮类抗生素的遗传信息及生物合成途径的研究进展

Progress on Genetic Information and Biosynthetic Pathways of Glycopeptide and Polyketide Antibiotics of Amycolatopsis

牛莎莎 1张萍 1牛春1
扫码查看

作者信息

  • 1. 宁夏泰瑞制药股份有限公司,银川 750100
  • 折叠

摘要

拟无枝菌属(Amycolatopsis)是万古霉素和利福霉素等次生代谢产物的菌株,该菌属天然抗生素的分子遗传学已经有了广泛研究.由于抗生素耐药率的上升,寻找新的药物来对抗感染治疗已成为当务之急.了解代谢产物遗传信息的新进展有助于合理地操纵生物合成途径,以便于研发新型抗生素.本文综述了近年来通过Amycolatopsis基因组序列发现的糖肽类和聚酮类抗生素及其生物合成途径方面的成果.

Abstract

The genus Amycolatopsis produces secondary metabolites like rifamycin and vancomycin,which are widely used in agriculture and medicine.This genus's natural antibiotics'molecular genetics have been thoroughly researched.Due to the rise in antibiotic resistance,finding new drugs to fight infections has become a priority.New advances in understanding the genetic information of metabolites can help rationally manipulate biosynthetic pathways for the development of new natural antibiotics.In this review,we review the recent achievements of glycopeptide and polyketide antibiotics discovered by the Amycolatopis genome sequence and their biosynthetic pathways.

关键词

拟无枝酸菌/糖肽类抗生素/聚酮类抗生素/万古霉素/利福霉素/生物合成途径

Key words

Amycolatopsis/glycopeptide antibiotics/polyketide antibiotics/vancomycin/rifamycin/biosynthetic pathways

引用本文复制引用

出版年

2024
国外医药(抗生素分册)
中国医药集团总公司四川抗菌素工业研究所,中国医学科学院医药生物技术研究所

国外医药(抗生素分册)

影响因子:0.852
ISSN:1001-8751
参考文献量51
段落导航相关论文